Skip to Main Content

Advertisement

Umbrella Alt Text
header search
Search
Advanced Search
Skip Nav Destination

Targeting the AIB1 Oncogene through Mammalian Target of Rapamycin Inhibition in the Mammary Gland

Cancer Res (2006) 66 (23): 11381–11388.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
AIB1/SRC-3/NCOA3 function in estrogen receptor alpha positive breast cancer
  • Amber J. Kiliti
  • Ghada M. Sharif
  • Mary Beth Martin
  • Anton Wellstein
  • Anna T. Riegel
Frontiers in Endocrinology (2023) 14
Functional and Phenotypic Characterisations of Common Syngeneic Tumour Cell Lines as Estrogen Receptor-Positive Breast Cancer Models
  • Maria Lambouras
  • Charlotte Roelofs
  • Melrine Pereira
  • Emily Gruber
  • Jessica L. Vieusseux
  • Patrick Lanteri
  • Cameron N. Johnstone
  • Fenella Muntz
  • Sandra O’Toole
  • Lisa M. Ooms
  • Christina A. Mitchell
  • Robin L. Anderson
  • Kara L. Britt
International Journal of Molecular Sciences (2023) 24 (6): 5666.
PELP1/SRC-3-dependent regulation of metabolic PFKFB kinases drives therapy resistant ER+ breast cancer
  • Thu H. Truong
  • Elizabeth A. Benner
  • Kyla M. Hagen
  • Nuri A. Temiz
  • Carlos Perez Kerkvliet
  • Ying Wang
  • Emilio Cortes-Sanchez
  • Chieh-Hsiang Yang
  • Marygrace C. Trousdell
  • Thomas Pengo
  • Katrin P. Guillen
  • Bryan E. Welm
  • Camila O. Dos Santos
  • Sucheta Telang
  • Carol A. Lange
  • Julie H. Ostrander
Oncogene (2021) 40 (25): 4384.
An AIB1 Isoform Alters Enhancer Access and Enables Progression of Early-Stage Triple-Negative Breast Cancer
  • Ghada M. Sharif
  • Moray J. Campbell
  • Apsra Nasir
  • Surojeet Sengupta
  • Garrett T. Graham
  • Max H. Kushner
  • William B. Kietzman
  • Marcel O. Schmidt
  • Gray W. Pearson
  • Olivier Loudig
  • Susan Fineberg
  • Anton Wellstein
  • Anna T. Riegel
Cancer Research (2021) 81 (16): 4230.
Cytoplasmic ERα and NFκB Promote Cell Survival in Mouse Mammary Cancer Cell Lines
  • Emily Smart
  • Luis H. Alejo
  • Jonna Frasor
Hormones and Cancer (2020) 11 (2): 76.
Cancer Stem Cell Phenotypes in ER+ Breast Cancer Models Are Promoted by PELP1/AIB1 Complexes
  • Thu H. Truong
  • Hsiangyu Hu
  • Nuri A. Temiz
  • Kyla M. Hagen
  • Brian J. Girard
  • Nicholas J. Brady
  • Kathryn L. Schwertfeger
  • Carol A. Lange
  • Julie H. Ostrander
Molecular Cancer Research (2018) 16 (4): 707.
PPARs as determinants of the estrogen receptor lineage: use of synthetic lethality for the treatment of estrogen receptor-negative breast cancer
  • Robert I. Glazer
  • Levy Kopelovich
Oncotarget (2017) 8 (31): 50337.
PPARδas a Metabolic Initiator of Mammary Neoplasia and Immune Tolerance
  • Robert I. Glazer
PPAR Research (2016) 2016: 1.
Prior Adjuvant Tamoxifen Treatment in Breast Cancer Is Linked to Increased AIB1 and HER2 Expression in Metachronous Contralateral Breast Cancer
  • Sara Alkner
  • Pär-Ola Bendahl
  • Anna Ehinger
  • Kristina Lövgren
  • Lisa Rydén
  • Mårten Fernö
  • William B. Coleman
PLOS ONE (2016) 11 (3): e0150977.
miR-137 Targets p160 Steroid Receptor Coactivators SRC1, SRC2, and SRC3 and Inhibits Cell Proliferation
  • Vijay Kumar Eedunuri
  • Kimal Rajapakshe
  • Warren Fiskus
  • Chuandong Geng
  • Sue Anne Chew
  • Christopher Foley
  • Shrijal S. Shah
  • John Shou
  • Junaith S. Mohamed
  • Cristian Coarfa
  • Bert W. O'Malley
  • Nicholas Mitsiades
Molecular Endocrinology (2015) 29 (8): 1170.
Characterization of a Steroid Receptor Coactivator Small Molecule Stimulator that Overstimulates Cancer Cells and Leads to Cell Stress and Death
  • Lei Wang
  • Yang Yu
  • Dar-Chone Chow
  • Fei Yan
  • Chih-Chao Hsu
  • Fabio Stossi
  • Michael A. Mancini
  • Timothy Palzkill
  • Lan Liao
  • Suoling Zhou
  • Jianming Xu
  • David M. Lonard
  • Bert W. O’Malley
Cancer Cell (2015) 28 (2): 240.
Androgen Receptor Is the Key Transcriptional Mediator of the Tumor Suppressor SPOP in Prostate Cancer
  • Chuandong Geng
  • Kimal Rajapakshe
  • Shrijal S. Shah
  • John Shou
  • Vijay Kumar Eedunuri
  • Christopher Foley
  • Warren Fiskus
  • Mahitha Rajendran
  • Sue Anne Chew
  • Martin Zimmermann
  • Richard Bond
  • Bin He
  • Cristian Coarfa
  • Nicholas Mitsiades
Cancer Research (2014) 74 (19): 5631.
Combined SFK/mTOR Inhibition Prevents Rapamycin-Induced Feedback Activation of AKT and Elicits Efficient Tumor Regression
  • Jennifer L. Yori
  • Kristen L. Lozada
  • Darcie D. Seachrist
  • Jonathan D. Mosley
  • Fadi W. Abdul-Karim
  • Christine N. Booth
  • Chris A. Flask
  • Ruth A. Keri
Cancer Research (2014) 74 (17): 4762.
Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells
  • Albana Gattelli
  • Ivan Nalvarte
  • Anne Boulay
  • Tim C. Roloff
  • Martin Schreiber
  • Neil Carragher
  • Kenneth K. Macleod
  • Michaela Schlederer
  • Susanne Lienhard
  • Lukas Kenner
  • Maria I. Torres‐Arzayus
  • Nancy E. Hynes
EMBO Molecular Medicine (2013) 5 (9): 1335.
PPARδ Induces Estrogen Receptor-Positive Mammary Neoplasia through an Inflammatory and Metabolic Phenotype Linked to mTOR Activation
  • Hongyan Yuan
  • Jin Lu
  • Junfeng Xiao
  • Geeta Upadhyay
  • Rachel Umans
  • Bhaskar Kallakury
  • Yuhzi Yin
  • Michael E. Fant
  • Levy Kopelovich
  • Robert I. Glazer
Cancer Research (2013) 73 (14): 4349.
Everolimus
  • Monique P. Curran
Pediatric Drugs (2012) 14 (1): 51.
Role of Estrogen Receptor Signaling in Breast Cancer Metastasis
  • Sudipa Saha Roy
  • Ratna K. Vadlamudi
International Journal of Breast Cancer (2012) 2012: 1.
Antiproliferative effects of selective cyclooxygenase-2 inhibitor modulated by nimotuzumab in estrogen-dependent breast cancer cells
  • Ying-Xue Wang
  • Jin-Xiang Gao
  • Xiu-Yun Wang
  • Li Zhang
  • Chang-Mei Liu
Tumor Biology (2012) 33 (4): 957.
The role of AIB1 in breast cancer
  • ALAN K. CHANG
  • HUIJIAN WU
Oncology Letters (2012) 4 (4): 588.
Akt and p53 are potential mediators of reduced mammary tumor growth by Chloroquine and the mTOR inhibitor RAD001
  • Christian R. Loehberg
  • Pamela L. Strissel
  • Ralf Dittrich
  • Reiner Strick
  • Juergen Dittmer
  • Angela Dittmer
  • Ben Fabry
  • Willi A. Kalender
  • Thorsten Koch
  • David L. Wachter
  • Nicole Groh
  • Astrid Polier
  • Ina Brandt
  • Laura Lotz
  • Inge Hoffmann
  • Florentine Koppitz
  • Sonja Oeser
  • Andreas Mueller
  • Peter A. Fasching
  • Michael P. Lux
  • Matthias W. Beckmann
  • Michael G. Schrauder
Biochemical Pharmacology (2012) 83 (4): 480.
Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer
  • Min Ni
  • Yiwen Chen
  • Elgene Lim
  • Hallie Wimberly
  • Shannon T. Bailey
  • Yuuki Imai
  • David L. Rimm
  • X. Shirley Liu
  • Myles Brown
Cancer Cell (2011) 20 (1): 119.
Proteomic Analysis of Pathways Involved in Estrogen-Induced Growth and Apoptosis of Breast Cancer Cells
  • Zhang-Zhi Hu
  • Benjamin L. Kagan
  • Eric A. Ariazi
  • Dean S. Rosenthal
  • Lihua Zhang
  • Jordan V. Li
  • Hongzhan Huang
  • Cathy Wu
  • V. Craig Jordan
  • Anna T. Riegel
  • Anton Wellstein
  • Rakesh K. Srivastava
PLoS ONE (2011) 6 (6): e20410.
Estrogen-Dependent and Estrogen-Independent Mechanisms Contribute to AIB1-Mediated Tumor Formation
  • Maria I. Torres-Arzayus
  • Jin Zhao
  • Roderick Bronson
  • Myles Brown
Cancer Research (2010) 70 (10): 4102.
Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
  • James C. Yao
  • Catherine Lombard-Bohas
  • Eric Baudin
  • Larry K. Kvols
  • Philippe Rougier
  • Philippe Ruszniewski
  • Sakina Hoosen
  • Jessica St. Peter
  • Tomas Haas
  • David Lebwohl
  • Eric Van Cutsem
  • Matthew H. Kulke
  • Timothy J. Hobday
  • Thomas M. O'Dorisio
  • Manisha H. Shah
  • Guillaume Cadiot
  • Gabriele Luppi
  • James A. Posey
  • Bertram Wiedenmann
Journal of Clinical Oncology (2010) 28 (1): 69.
Disruption of the SRC-1 gene in mice suppresses breast cancer metastasis without affecting primary tumor formation
  • Shu Wang
  • Yuhui Yuan
  • Lan Liao
  • Shao-Qing Kuang
  • Jean Ching-Yi Tien
  • Bert W. O'Malley
  • Jianming Xu
Proceedings of the National Academy of Sciences (2009) 106 (1): 151.
The potential role of estrogen receptors and the SRC family as targets for the treatment of breast cancer
  • Melanie Spears
  • John Bartlett
Expert Opinion on Therapeutic Targets (2009) 13 (6): 665.
The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer
  • Tyler Lahusen
  • Ralf T. Henke
  • Benjamin L. Kagan
  • Anton Wellstein
  • Anna T. Riegel
Breast Cancer Research and Treatment (2009) 116 (2): 225.
Mechanism of action of everolimus in renal cell carcinoma
  • Bernard Escudier
  • John A. Thompson
Medical Oncology (2009) 26 (S1): 32.
Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-α-dependent and estrogen receptor-α-independent mechanisms
  • Xinghua Long
  • Meiyun Fan
  • Robert M. Bigsby
  • Kenneth P. Nephew
Molecular Cancer Therapeutics (2008) 7 (7): 2096.
CD151 Accelerates Breast Cancer by Regulating α6 Integrin Function, Signaling, and Molecular Organization
  • Xiuwei H. Yang
  • Andrea L. Richardson
  • Maria I. Torres-Arzayus
  • Pengcheng Zhou
  • Chandan Sharma
  • Alexander R. Kazarov
  • Milena M. Andzelm
  • Jack L. Strominger
  • Myles Brown
  • Martin E. Hemler
Cancer Research (2008) 68 (9): 3204.
Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data
  • Chiaki Tanaka
  • Terence O’Reilly
  • John M. Kovarik
  • Nicholas Shand
  • Katharine Hazell
  • Ian Judson
  • Eric Raymond
  • Sabine Zumstein-Mecker
  • Christine Stephan
  • Anne Boulay
  • Marc Hattenberger
  • George Thomas
  • Heidi A. Lane
Journal of Clinical Oncology (2008) 26 (10): 1596.
The UPS: a promising target for breast cancer treatment
  • Ko Sato
  • Eeson Rajendra
  • Tomohiko Ohta
BMC Biochemistry (2008) 9 (S1)
Epidermal Growth Factor Receptor Tyrosine Phosphorylation and Signaling Controlled by a Nuclear Receptor Coactivator, Amplified in Breast Cancer 1
  • Tyler Lahusen
  • Mark Fereshteh
  • Annabell Oh
  • Anton Wellstein
  • Anna T. Riegel
Cancer Research (2007) 67 (15): 7256.
Targeted Agents: The Rules of Combination
  • Eunice L. Kwak
  • Jeffrey W. Clark
  • Bruce Chabner
Clinical Cancer Research (2007) 13 (18): 5232.
Hedgehog Pathway Expression in Heterogeneous Pancreatic Adenocarcinoma: Implications for the Molecular Analysis of Clinically Available Biopsies
  • Adam Steg
  • Selwyn M. Vickers
  • Mohamad Eloubeidi
  • Wenquan Wang
  • Isam A. Eltoum
  • William E. Grizzle
  • M. Wasif Saif
  • Al F. Lobuglio
  • Andra R. Frost
  • Martin R. Johnson
Diagnostic Molecular Pathology (2007) 16 (4): 229.
The mTOR pathway inhibitor RAD001 (everolimus) is highly efficacious in tamoxifen-sensitive and -resistant breast cancer xenografts
  • Diana Behrens
  • Anne E. Lykkesfeldt
  • Iduna Fichtner
Targeted Oncology (2007) 2 (3): 135.
Phase I Study of Everolimus in Pediatric Patients With Refractory Solid Tumors
  • Maryam Fouladi
  • Fred Laningham
  • Jianrong Wu
  • Melinda A. O'Shaughnessy
  • Kristen Molina
  • Alberto Broniscer
  • Sheri L. Spunt
  • Inga Luckett
  • Clinton F. Stewart
  • Peter J. Houghton
  • Richard J. Gilbertson
  • Wayne L. Furman
Journal of Clinical Oncology (2007) 25 (30): 4806.
Modeling Migration and Metastasis in Drosophila
  • Anna C.-C. Jang
  • Michelle Starz-Gaiano
  • Denise J. Montell
Journal of Mammary Gland Biology and Neoplasia (2007) 12 (2-3): 103.
  • Online ISSN 1538-7445
  • Print ISSN 0008-5472

AACR Journals

 

 

  • Copyright © 2023 by the American Association for Cancer Research.
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept